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A CONSENSUS PARAMETER FOR THE EVALUATION AND
MANAGEMENT OF ANGIOEDEMA IN THE EMERGENCY
DEPARTMENT
Joseph J. Moellman, M.D., Jonathan A. Bernstein, MD, and Christopher Lindsell, Ph.D.
I. INTRODUCTION AND RATIONALE FOR DEVELOPMENT
A. Overview
Angioedema is a physical sign secondary to swelling of the subcutaneous or submucosal
tissues, and is due to enhanced vascular permeability, which allows movement of fluid from
the vascular space into the interstitial space. Angioedema is non-pitting, non-dependent and
transient (lasting up to 7 days). It is critical to distinguish angioedema from edema, which is
pitting, dependent and persistent. Angioedema may be life-threatening, depending in large
part on its underlying cause and body location. Thus, the clinical approach to a patient
presenting in the emergency department (ED) with angioedema should include a
consideration of potential causes. This document is meant to provide the ED physician with
a practical framework for classifying angioedema, and to outline management based on this
classification.
Most ED visits for angioedema will involve allergic or idiopathic angioedema, with or
without concomitant urticaria or evidence of anaphylaxis. These forms of angioedema are
typically mediated by histamine, and their management is usually familiar to ED staff. The
key challenge in the management of angioedema in the ED, however, is recognizing and
treating potential non-histaminergic (bradykinin-mediated) angioedema. Unlike histamine-
mediated angioedema, bradykinin-mediated angioedema is not associated with urticaria,
does not respond to antihistamines or corticosteroids, and is poorly responsive to
epinephrine. Bradykinin-mediated angioedema tends to be more severe, longer lasting, and
much more likely to involve concurrent abdominal symptoms than histamine-mediated
angioedema.
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B. Epidemiology
When angioedema develops, it often leads to an urgent (unscheduled) office or ED visit.
Population-based data are lacking, but it is likely that patients with new-onset or recurring
angioedema will go to the ED. Although anecdotal, this behavior fits that of pediatric
patients with anaphylaxis; data suggest that roughly three-fourths of these children are
managed in the ED.(1)
Few studies have examined the epidemiology of ED visits for angioedema. To date, all
studies have relied on the International Classification of Diseases, 9th Edition, Clinical
Modification (ICD9CM) code 995.1 to identify cases. Using this approach is limited, as the
sensitivity and specificity of ICD9CM criteria to identify angioedema are currently
unknown. Findings by Clark and colleagues, who demonstrated the low sensitivity and
clinically relevant bias that comes from using ICD9CM anaphylaxis codes as the only
source of case identification, further emphasize the need to overcome these methodological
issues in order to generate more accurate epidemiologic data on angioedema.(2)
Based on data from the National Hospital Ambulatory Medical Care Survey (NHAMCS),
there are as many as 80,000 to 112,000 ED visits for angioedema annually.(3, 4) The
hospitalization rate for angioedema was 4.0 per 100,000 in 2005, making this condition the
“dominant allergic disorder that results in hospitalization in the United States.” (5) About
18% of ED visits coded as angioedema result in hospitalization.(4) However, understanding
the true epidemiology of angioedema is hampered by persistent confusion among clinicians
about the case definition and, more specifically, the distinction between different groups of
allergic reactions that might present to the ED including: 1) anaphylaxis with angioedema;
2) an isolated angioedema disorder or; 3) other related conditions such as chronic urticaria
with angioedema. This consensus parameter focuses on the presentation of isolated
angioedema disorders to the ED.
Angioedema disorders are the result of either bradykinin- or histamine- mediated responses.
(6) Many different factors are associated with the bradykinin- mediated angioedema
disorders, most notably hereditary conditions and specific types induced by medication. Up
to 50% of hereditary angioedema (HAE) patients in the United States experiencing attacks
have historically been reported to require an ED visit, with the majority of these patients
requiring hospitalization.(4) A chart review conducted at five academic EDs revealed that
30% of adult ED patients with angioedema had angiotensin-converting enzyme (ACE)
inhibitor-induced angioedema, with 18% of these being admitted to an observation unit,
12% being admitted to an inpatient unit and 11% being admitted to an intensive care unit
(ICU).(7) Bluestein and colleagues also found that 30% of angioedema cases in the ED were
induced by ACE-inhibitors, although they noted a lower admission rate of 14% in their
community setting.(8) The possibility of medication-induced angioedema in children should
also not be ignored. Although rare, in one study of 42 cases of pediatric angioedema, 7%
(n=3) presented with upper airway obstruction and were taking either an ACE inhibitor or
calcium channel blocker.(9)
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C. Classification
It is difficult, if not sometimes impossible, to establish a precise cause of swelling in a
patient presenting with angioedema in the ED. Therefore, it is recommended that patients be
categorized using the following classification (Table 1): 1) anaphylaxis; 2) histaminergic
angioedema without anaphylaxis (including both allergic and idiopathic angioedema); and
3) non-histaminergic angioedema (including both hereditary angioedema [HAE] and ACE
inhibitor [ACEI]-induced angioedema). Because the pathophysiology of these groups is
different, the clinical manifestations and optimal treatments also differ. Unlike histamine-
mediated angioedema, bradykinin-mediated angioedema does not respond to antihistamines
or corticosteroids and is only poorly responsive to epinephrine. Bradykinin-mediated
angioedema tends to be more severe, longer-lasting, and much more likely to involve the
abdominal viscera than histamine-mediated angioedema.(10) Bradykinin-mediated
angioedema also frequently involves the upper airway, with a significant risk of death due to
asphyxiation.(11) Figure 1 illustrates the general approach to classifying and managing
angioedema in the ED. Details of the evaluation and management are expounded below.
D. Rationale for Development of a Parameter for ED Angioedema Management
The growing body of evidence describing the underlying mechanisms resulting in
angioedema presenting to the ED provides the foundation necessary to care for these
patients. Likewise, with the recent development and availability of novel pharmaceutical
agents to treat bradykinin-mediated angioedema, it has become paramount that ED
physicians be able to distinguish between histamine-mediated and bradykinin-mediated
etiologies.
E. The practice parameter developmental process
In the following sections, we discuss recommendations for the evaluation, management and
follow-up of the angioedema patient presenting to the ED. These recommendations were
developed collaboratively among a group of allergists and emergency medicine physicians
with expertise in this area. This consensus parameter was developed following a rigorous
process to maximize use of available evidence.
The workgroup included experts in the specialties of Emergency Medicine and Allergy and
Immunology. The Chairs, Joseph Moellman, M.D. and Jonathan Bernstein, MD, invited
workgroup members to participate in the parameter development. The charge to the
workgroup was to use a systematic literature review, in conjunction with consensus expert
opinion and workgroup-identified supplementary documents to develop practice parameters
that provide a comprehensive approach for an assessment and management of angioedema
in the Emergency Department. A search of the medical literature was performed for a
variety of terms that were considered to be relevant to this practice parameter. Literature
searches were performed on PubMed, Google Scholar, and the Cochrane Database of
Systematic Reviews. All reference types were included in the results. References identified
as being relevant were searched for relevant references, and those references also were
searched for relevant references. In addition, members of the workgroup were asked for
references that may have been missed by this initial search. Published clinical studies were
rated by category of evidence and utilized to establish the strength of the recommendations.
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Each individual element of the recommendations was derived by an allergist-emergency
physician team pair. Elements were then combined into a parameter during an in-person
conference. The approach taken was to generate a practical, evidence-based tool that could
be used by emergency medicine physicians to guide their practice. The consensus parameter
includes an executive summary of recommendations. Each recommendation is supported by
a discussion of the literature. Lastly, participants identified areas where lack of evidence
suggests a role for future research, as well as possible barriers to implementation of the
parameter. The parameter was appraised by external reviewers identified by the workgroup
as experts in the field of Emergency Medicine and Allergy and Immunology. Based on this
process this parameter represents an evidence-based, broadly accepted consensus document.
EXECUTIVE SUMMARY
Angioedema can be classified as either bradykinin-mediated or histamine-mediated
angioedema. Angioedema secondary to ACE inhibitors is a common side effect of this class
of drugs and occurs when decreased metabolism of bradykinin leads to excess accumulation.
Hereditary angioedema type I and type II are forms of angioedema due to a functionally
abnormal C1-inhibitor (C1-INH) gene that results in the overproduction of bradykinin.
Hereditary angioedema with normal C1-inhibitor function with or without a genetic defect
has been well- described, but to date only indirect anecdotal evidence supports bradykinin as
the mediator. Acquired C1 inhibitor deficiency clinically resembles HAE but the low C1-
INH is from consumption of the protein due to an underlying lymphoproliferative disorder
and/or an antibody directed against C1-INH resulting in the overproduction of bradykinin.
Most idiopathic angioedema is thought to be histamine- mediated and is frequently
responsive to H1-antagonists, epinephrine and corticosteroids; however, refractory cases
may be secondary to bradykinin. In patients with idiopathic angioedema unresponsive to
H1-antagonists, epinephrine and corticosteroids, without a family history of angioedema, in
the absence of direct evidence for bradykinin as the primary mediator of swelling, it would
be premature to recommend the use of therapies approved for HAE.
Different types of angioedema have various historical features that are helpful for
determining the putative cause. The physical exam of the angioedema patient should focus
initially on vital signs and proceed to a targeted, focused exam of the airway, integumentary
and abdominal regions. There are no point-of-care or laboratory based tests available in the
ED to provide immediate guidance on treatment to the emergency medicine physician.
However, C4 and tryptase levels should be considered to assist in the diagnosis of HAE and
angioedema associated with anaphylaxis, respectively. Results of these labs when drawn
during an angioedema attack are particularly useful during follow-up with a primary care
physician, allergist or angioedema specialist and on return of the patient to the ED.
All patients with head and neck angioedema with any lingual involvement, as well as those
with upper airway complaints, may benefit from flexible fiberoptic laryngoscopy, if
immediately available, to determine the extent of involvement of the base of the tongue and
the larynx. This is necessary to determine the possible need for airway management and the
appropriate disposition of the patient. Radiographic techniques for assessment of the airway
in patients presenting with acute angioedema have limited utility, and the unavoidable delay
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and reduced medical observation caused by these procedures may impose unnecessary risk.
General monitoring of angioedema patients in the ED should be performed in a similar
manner to the approach taken for patients with other respiratory or airway complaints, which
includes close monitoring of oxygen saturation, cardiac status, and clinical signs and
symptoms. Maneuvers such as supplemental oxygen, nasal trumpets and bag-valve mask
ventilation may be useful temporizing measures for the angioedema patient with mild
airway involvement, but are not a substitute for intubation if there is any concern about
airway compromise. The decision to intubate or perform a more aggressive procedure
should be based on the physician’s assessment of the patient’s prior history, airway
anatomy, other co-morbidities and objective nasopharyngeal findings. When invasive airway
management is indicated, maneuvers may involve the placement of an endotracheal tube,
which requires patient sedation and analgesia to ameliorate significant discomfort. Once the
decision to intubate is made, a rescue plan should be in place that involves having
alternative airway devices available as rescue devices, as well as the means to perform a
cricothyrotomy if necessary.
Treatment of angioedema depends on historical features of the patient and, if available, their
preexisting diagnosis. If angioedema presents with signs of anaphylaxis (urticaria, asthma,
hypotension) epinephrine is recommended. Standard treatment for histamine-mediated
angioedema includes H1 and H2 antagonists and corticosteroids and may require
epinephrine in life-threatening situations. While generally not effective for bradykinin-
mediated angioedema, these treatments are not contraindicated and if a putative cause of
angioedema is unknown, epinephrine followed by H1 antagonists and corticosteroids should
be given. The only potential acute treatment currently readily available for the treatment of
ACE-induced or other bradykinin-mediated angioedema in the ED is fresh frozen plasma,
which has a risk of viral transmission, allergic reactions and volume overload, and a
possibility of worsening symptoms in HAE. Several targeted therapies are now FDA
approved in the United States for the treatment of acute HAE attacks. These novel therapies,
including icatibant, ecallantide and C1-inhibitor concentrate, are effective for the treatment
of HAE attacks and may have benefit in ACE-induced angioedema, but data are limited to
support these treatments for non-HAE patients. There is a paucity of data to guide
disposition decisions for hospitalization versus discharge home for angioedema patients. The
Ishoo criteria provide one potential way for a physician to assess risk and admission
decisions; however, these criteria have not yet been validated.
I. ANGIOEDEMA: DEFINITIONS
Summary Statement 1. Angioedema can be classified as either bradykinin-
mediated or histamine-mediated angioedema.(LB)—Histamine-mediated
angioedema is often associated with urticaria and with swelling episodes that typically
resolve within 24 to 48 hours. Causes include drugs, foods, latex and insect stings.
Bradykinin-mediated angioedema is not mediated by immunoglobulin IgE antibodies and is
not associated with urticaria. Swelling attacks in bradykinin-mediated angioedema typically
last 2–5 days and are characteristically unresponsive to antihistamines and/or
corticosteroids. (6, 12–14)
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Summary Statement 2. Angioedema secondary to ACE inhibitors is a common
side effect of this class of drugs and occurs when decreased metabolism of
bradykinin leads to excess accumulation. (LB)—Angioedema is a well-known side
effect associated with use of ACE inhibitors. About 0.1% to 0.7% of patients treated with
these agents are estimated to develop angioedema, characterized mostly by edema of the lips
and tongue.(15, 16) African-Americans and patients on immunosuppressants tend to be at
higher risk.(17) The rate of development of angioedema has been shown to be the highest
during the first 30 days of initiation of ACE inhibitor therapy and thereafter declines in
incidence. However, there is still an increased rate of ACE inhibitor angioedema even in
patients taking ACE therapy for longer than one year (18). The treatment of choice is
discontinuing all ACE inhibitors. Even after discontinuing the ACE inhibitor, patients may
be at increased risk of a subsequent angioedema attack for many weeks. In patients who do
not discontinue the ACE inhibitor, the average time to the next angioedema event is 10
months.(19) The mediator of angioedema is bradykinin.
It is notable that other drugs affecting the renin-angiotensin system such as angiotensin
receptor blockers and renin antagonists have been shown to cause angioedema, but
secondary to a different unknown mechanism. Other non-histamine-mediated drug reactions
include angioedema associated with inhibition of cyclooxygenase leading to an
accumulation of leukotriene mediators as seen with reactions to non-steroidal anti-
inflammatory drugs (NSAIDs).(20) Patients with this condition usually manifest with
urticaria and facial swelling upon exposure to the drug, but can present with swelling only.
(20)
Summary Statement 3. Hereditary angioedema type I and type II are forms of
angioedema due to a functionally abnormal C1-inhibitor (C1-INH) gene that
results in the overproduction of bradykinin. (LB)—Hereditary angioedema is a rare
form of angioedema that affects approximately 1:50,000 in the general population.(21)
Angioedema of this type usually begins in childhood or young adulthood and may worsen at
puberty.(21) Fifty percent of patients manifest recurrent episodes of swelling or abdominal
pain by the age of 10.(22) The underlying cause is a mutation of the gene encoding the C1
inhibitor, which is inherited in an autosomal dominant pattern with relatively high
penetrance. Two subtypes are recognized. Type I, which comprises 85% of cases, has low
antigenic and functional C1 inhibitor levels. Patients with normal or high antigenic C1
inhibitor levels but abnormal C1 inhibitor function are referred to as Type II.(21, 23, 24)
Type II HAE is caused by synthesis of a dysfunctional C1-INH protein.(23–25) HAE due to
C1 inhibitor deficiency has been shown to be mediated by bradykinin.(26) Many patients
experience prodromal symptoms prior to an attack. A prominent prodromal symptom is
erythema marginatum. This is an erythematous serpentine but non-pruritic and non-raised
rash that should not be confused with urticaria.(27)
Summary Statement 4. Hereditary angioedema with normal C1 inhibitor
function with or without a genetic defect has been well-described but to date
only indirect anecdotal evidence supports bradykinin as the mediator. (C, LB)
—Hereditary angioedema in patients with normal complement levels and normal C1-
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inhibitor, but a well-defined family history of angioedema, is believed to be an autosomal
dominant condition with low penetrance.(16, 28) Patients tend to present at a slightly older
age compared to HAE due to C1-INH deficiency. It is reported more frequently in women
and attacks are characteristically more common in the facial region, especially tongue
swelling. When affected, men tend to have less severe and less frequent attacks. Taking
estrogen- containing therapies increases attack frequency in most patients.(28, 29) A
minority of these patients has a mutation in the gene encoding coagulation factor XII, but
the underlying cause of angioedema is unknown.(16, 29) Bradykinin is presumed to be the
mediator of swelling in these patients since most appear to respond to the same medications
used to treat HAE with C1 inhibitor deficiency but not to H1-antagonists, corticosteroids
and epinephrine.(16, 21)
Summary Statement 5. Acquired C1 inhibitor deficiency clinically resembles
HAE but the low C1-INH is from consumption of the protein due to an
underlying lymphoproliferative disorder and/or an antibody directed against
C1-INH resulting in the overproduction of bradykinin.(B, LB)—Acquired
angioedema with C1 inhibitor deficiency clinically resembles HAE due to C1 inhibitor
deficiency but is not familial and tends to present in individuals over 40 years of age.
Acquired C1 inhibitor deficiency results from excessive C1 inhibitor catabolism, which in
approximately 15% of these cases is due to an underlying lymphoproliferative disorder
and/or an autoantibody directed against C1-INH.(16, 30–32) The most common underlying
disorders are lymphoreticular disorders (ranging from monoclonal gammopathy of unknown
significance to lymphomas), but a variety of other malignancies and autoimmune disorders
have been linked to the disease. In all cases, the mediator of swelling is bradykinin.
Summary Statement 6. Most idiopathic angioedema is thought to be
histamine-mediated and is frequently responsive to H1-antagonists,
epinephrine and corticosteroids; however, refractory cases may be secondary
to bradykinin. In patients with idiopathic angioedema unresponsive to H1-
antagonists, epinephrine and corticosteroids, without a family history of
angioedema, in the absence of direct evidence for bradykinin as the primary
mediator of swelling, it would be premature to recommend the use of
therapies approved for HAE. (C)—Most patients with idiopathic angioedema are
responsive to H1-antagonists, epinephrine and corticosteroids; however, there is a small
group of patients with idiopathic angioedema who do not respond to H1-antagonists, and
refractory cases may be secondary to bradykinin. There is limited and weak evidence that
the mediator of swelling is bradykinin in this small subset of patients.
II. EVALUATION: HISTORY
Figure 1 summarizes how elements of the history and physical examination should help to
establish the working diagnosis.
Summary Statement 7. Different types of angioedema have various historical
features that are helpful for determining the putative cause.(B)—Table 2
summarizes the historical characteristics of different types of angioedema. Although these
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characteristics do not directly distinguish one type of angioedema from another, they can
help guide the emergency medicine physician toward the best possible treatment course.
III. EVALUATION: PHYSICAL EXAMINATION
Summary Statement 8. The physical exam of the angioedema patient should
focus initially on vital signs and proceed to a targeted, focused exam of the
airway, integumentary and abdominal regions. (D)
Vital signs: Although patients with either bradykinin- or histamine-mediated angioedema
may have normal hemodynamic parameters, a number of patients may exhibit profound
hypotension, tachycardia and respiratory failure secondary to fluid shifts and airway edema.
Due to vasodilation and increased vascular permeability, both bradykinin- and histamine-
mediated angioedema have the potential to cause hypovolemic shock due to the shift of
fluids in various bodily compartments. More importantly, asphyxiation secondary to airway
edema is the leading cause of death in such patients and thus it is essential to recognize
subtle aspects of stridor and voice change in such patients immediately.(33)
Head and Neck: A focused, detailed oropharyngeal exam is essential in evaluating patients
with either bradykinin- or histamine-mediated angioedema, specifically noting any edema in
the lips, tongue, soft palate or posterior pharynx since many treatment algorithms are
determined by the specific region of the oropharynx affected. In particular, any presence of
stridor or hoarseness must be noted since further diagnostic tests may be necessary such as
nasopharyngoscopy.(33)
Although oropharyngeal involvement can occur with either bradykinin- or histamine-
mediated angioedema, it is more commonly seen in bradykinin-mediated angioedema. Over
half of the patients with HAE have at least one episode of laryngeal edema during their
lifetime. In the past, 30% of deaths in patients with HAE were due to laryngeal edema.(11,
34) In patients with ACE inhibitor induced angioedema, the head and neck is the site most
commonly affected.
Integumentary: The characteristic physical exam finding in bradykinin-mediated
angioedema is a firm, non-pruritic swelling resulting from the accumulation of fluid in the
reticular dermis and subcutaneous or submucosal tissue. The lesions are sometimes tender to
palpation and are non-pitting. Histamine- mediated angioedema involves the deeper dermis
and tends to be more commonly associated with urticarial lesions that are discrete, pruritic
erythematous papules in the epidermis that blanch with pressure. Both lesions arise from
local vasodilatation and increased vascular permeability. Although it is uncommon to have
urticarial lesions in bradykinin-mediated angioedema, some studies suggest that up to 50%
of patients with histamine-mediated angioedema may present with both angioedema and
urticarial lesions.(21, 35, 36) In HAE, the most common sites of edema include the arms,
legs, hands and feet.(21)
Abdomen: Patients with bradykinin- or histamine-mediated angioedema may present with
gastrointestinal symptoms. However, a patient presentation consistent with an “acute
surgical abdomen” on exam, with severe tenderness, guarding and rebound tenderness due
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to bowel wall edema is much more characteristic of HAE patients. Cases of unnecessary
abdominal surgery have been documented in HAE patients.(21)
IV. EVALUATION: ANCILLARY TESTING
Summary Statement 9. There are no point-of-care or laboratory based tests
available in the ED to provide immediate guidance on treatment to the
emergency medicine physician. However, C4 and tryptase levels should be
considered to assist in the diagnosis of HAE and angioedema associated with
anaphylaxis, respectively. Results of these labs when drawn during an
angioedema attack are particularly useful during follow-up with a primary care
physician or angioedema specialist or upon return of the patient to the ED.
(LB)—Almost all patients with HAE types I and II have a persistently low serum C4 level;
C4 is an excellent screening tool for C1 inhibitor deficiency states.(13, 21, 37) C4 levels
combined with C1 inhibitor level and C1 inhibitor function (<50% using the chromogenic
assay or <68% using the quidel assay) can be used to differentiate between Type I and Type
II HAE, and HAE that is not mediated by C1 inhibitor deficiency.(38) If C4 is normal
during an attack in a patient not on androgens or C1-inhibitor replacement, proceeding to C1
inhibitor analysis is unnecessary.(13) Currently, the C4 test is not recommended for patients
younger than one year because of its unreliability in this age group. C1 inhibitor and C4
concentrations increase to adult levels between 2 and 3 years of age.(39) The chromogenic
functional C1 inhibitor assay appears to be superior to the ELISA-based (quidel) C1
inhibitor functional assay.(37)
Serum tryptase levels are sometimes considered in differentiating various causes of
angioedema. Tryptase is normal in hereditary angioedema I and II and may be elevated in
cases of anaphylaxis or other mast cell-mediated disorders manifesting with angioedema. An
elevated tryptase level can be helpful in ruling out hereditary angioedema although a normal
tryptase level provides no discriminatory information.
Laboratory testing is of little use to the ED evaluation and management of the patient with
angioedema. Measurement of C4 and tryptase levels to discriminate between bradykinin-
and histamine-mediated angioedema, respectively typically takes longer to process and
provide results than the time-frame in which management decisions must be made in the
ED. By the time testing is complete, it is known whether or not the patient has responded to
H1-antagonists, corticosteroids and epinephrine, and thus the likely mechanism for the
attack can be surmised. Laboratory testing at the time of an attack, however, can be useful
for the long-term management of patients with angioedema. For example, in 2–4% of cases
of HAE the C4 level is normal in between attacks but is low in virtually 100% during acute
angioedema attacks, and in these patients subsequent measurements of the antigenic and
functional C1 inhibitor level are helpful to evaluate for HAE Type I vs. Type II. (21, 37, 38)
Measuring the C4 level is an effective screening test to rule out HAE Type I and Type II,
and initiating this in the ED will ensure the patient has results available during follow-up
and subsequent ED visits.(21) It is not useful to screen with a CH50 or C3 complement
level.(38) It is prudent to obtain a C4 level in a patient with angioedema when no obvious
etiology is found, especially if the angioedema appears to be mediated by bradykinin.(39) It
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is important that C4 is sent to the laboratory in a timely fashion, as degradation and
artificially low C4 levels may be reported if there is a significant delay in transfer or poor
handling.(37)
Summary Statement 10. All patients with head and neck angioedema with any
lingual involvement, as well as those with upper airway complaints, may
benefit from flexible fiberoptic laryngoscopy, if immediately available, to
determine the extent of involvement of the base of the tongue and the larynx.
This is necessary to determine the possible need for airway management and
the appropriate disposition of the patient.(C)—In the perioral region and neck,
angioedema can involve any number of mucosal sites from the lips to the larynx, and the
involvement of these sites is random and can be noncontiguous.(33, 40–46) Angioedema of
the upper aerodigestive tract can be life-threatening if it causes airway compromise that is
not recognized and treated. A major question for emergency physicians is how and in who to
evaluate the airway beyond what can be seen on physical examination.(33, 40–46) Current
studies are of small sample size but suggest that any presentation of head and neck
angioedema can have associated swelling of the larynx, base of the tongue or both. We
recommend that those patients with involvement of the tongue, soft palate or floor of the
mouth should have direct visualization, if immediately available, of the base of tongue and
airway. Patients who do show involvement of these deeper structures may require airway
intervention or at least close monitoring in an intensive care unit with repeat laryngoscopy
depending on any changes in symptoms. Patients without involvement of these deeper
structures may be medically treated, observed for a number of hours to document resolution
of the swelling, and then discharged home.(33, 40–46). If nasopharyngoscopy is not
immediately available to the emergency physician, then the clinical assessment should
consider stridor, hoarseness, drooling and swelling as potential signs of airway involvement.
Summary Statement 11. Radiographic techniques for assessment of the
airway in patients presenting with acute angioedema have limited utility, and
the unavoidable delay and reduced medical observation caused by these
procedures may impose unnecessary risk.(C)—There is very little in the medical
literature regarding the use of neck x-rays or CT scans to help determine the extent of
airway involvement in a patient presenting with acute angioedema. The use of radiography
has most value in ruling out certain disease processes that may mimic angioedema, such as
an abdominal CT scan in the patient with acute abdominal pain. The use of laryngeal
ultrasonography may prove beneficial as a non-invasive tool to assess airway involvement,
yet no studies to date have explored its feasibility or utility.
V. TREATMENT: ACUTE AIRWAY MANAGEMENT OF ANGIOEDEMA
Summary Statement 12. General monitoring of angioedema patients in the ED
should be performed in a similar manner to the approach taken for patients
with other respiratory or airway complaints, which includes close monitoring
of oxygen saturation, cardiac status, and clinical signs and symptoms.(D)—
The approach to monitoring patients with angioedema is similar to the course taken with
other ED patients with either respiratory or airway complaints. All patients should be placed
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on a pulse oximeter and a cardiac monitor. Pulse oximetry is useful to determine initial
oxygenation during the primary assessment. Equally important, the physician can follow
pulse oximetry to note trends with time and therapy. Unfortunately, pulse oximetry may be a
late marker of airway issues and not be abnormal until there is significant upper airway
edema, at which point the patient could already be in significant respiratory distress. In
general, even if pulse oximetry is in the normal range for the patient, it should not be the
primary factor in the decision to intubate if there is concern about significant upper airway
compromise. Similarly, cardiac monitoring is helpful to determine if there are other causes
of the patient’s complaints, such as an arrhythmia or cardiac ischemia, or after potential
cardiac-stimulatory medications (epinephrine) have been given. As with pulse oximetry,
trends in cardiac monitoring may give an indication of whether the patient’s situation is
worsening or whether initial therapy is helping.
Capnography is a useful adjunct to monitor a patient’s respiratory status, and is a more
sensitive indicator of ventilation difficulties than pulse oximetry. However, similar to pulse
oximetry, patients with pending upper airway obstruction often have normal capnography
despite heading toward impending airway compromise. Capnography can be useful in two
other scenarios associated with angioedema: 1) monitoring the adequacy of ventilation after
intubation, and 2) monitoring the level of sedation associated with other medications that
may have been used for diagnostic (benzodiazepines/ketamine to facilitate
nasopharyngoscopy) or therapeutic (H1-antagonists in the initial management of
undifferentiated upper airway difficulties) purposes.
Summary Statement 13. Maneuvers such as supplemental oxygen, nasal
trumpets and bag-valve mask ventilation may be useful temporizing measures
for the angioedema patient with mild airway involvement, but are not a
substitute for intubation if there is any concern about airway compromise.(D)
—Supplemental oxygen may be considered for patients with airway or respiratory
complaints, and should be applied to those who are hypoxic. Nasopharyngeal airway devices
(i.e. nasal trumpets) may act as temporizing measures and may assist with bag-valve mask
ventilation. While bag-valve mask ventilation may temporarily be able to overcome the
airway obstruction, as the disease progresses to significant laryngeal involvement, bag-valve
mask ventilation will become very difficult. Non-invasive ventilation such as continuous
positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) may act as a
temporary measure to assist with ventilation in patients with hypercarbia. However, positive
pressure ventilation does not aid in stenting open the airway for a prolonged period of time
and is not definitive therapy.
Summary Statement 14. The decision to intubate or perform a more
aggressive procedure should be based on the physician’s assessment of the
patient’s prior history, airway anatomy, other co-morbidities and objective
nasopharyngeal findings.(D)—The decision to intubate can be based on 2 broad
approaches: 1) clinical gestalt and 2) objective evaluation. Clinical gestalt accounts for a
patient’s prior history, such as previous rapid progression to intubation, difficult airway
anatomy, or concomitant comorbidities that may impact the need and ease of intubation such
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as underlying cardiorespiratory disease. The objective evaluation combines physical
examination with nasopharyngoscopy findings. Findings such as a change in the patient’s
voice, hoarseness, and stridor should raise the suspicion for significant airway involvement
and the need for a definitive airway.(33) Further, examination of the oropharynx is also
important to differentiate those with primarily lip and anterior tongue swelling from others.
An objective evaluation may provide more specific information about where the edema is
occurring or how extensive the progression.
Because of the importance of differentiating upper and lower airway involvement, in
patients with throat or voice complaints it may be prudent to obtain direct visualization of
lower airway structures. Visualizing epiglottic, aryepiglottic or laryngeal edema should raise
concern for the need to secure the airway sooner than later. There are several methods to
facilitate this evaluation, including an awake intubation or nasopharyngoscopy. Both of
these approaches are discussed below. Tongue involvement should heighten one’s suspicion
of possible airway concerns, while pharyngeal or laryngeal involvement definitely warrant
close monitoring and consideration of early invasive airway management.
Summary Statement 15. When invasive airway management is indicated,
maneuvers may involve the placement of an endotracheal tube, which
requires patient sedation and analgesia to ameliorate significant discomfort.
Once the decision to intubate is made, a rescue plan should be in place that
involves having alternative airway devices available as rescue devices, as
well as the means to perform a cricothyrotomy if necessary.(C)
Choice of invasive maneuvers: Extraglottic and supraglottic devices have become common
rescue devices for use in the prehospital setting, the operating room, and the emergency
department. In many cases, they have also superseded endotracheal intubation as the
primary method of choice for securing a patient’s airway. However, they are not appropriate
for patients with angioedema. Since a high proportion of patients with lingual and laryngeal
involvement require intubation, there is a high likelihood that an extraglottic device will
remain above the airway obstruction.(33). While some extraglottic devices allow for blind
passage of an endotracheal tube through them, there is only a slim chance that a blindly
passed tube will be able to thread between the edematous tissues present in angioedema. In
fact, the trauma caused by the tube if it fails to pass may precipitate worsening symptoms. In
patients with angioedema who require airway management, endotracheal intubation is the
procedure of choice.
Induction agents: If a patient is not predicted to have a difficult airway and laryngoscopy is
to be performed, standard induction and paralytic agents should be chosen. Etomidate is
frequently used in the ED management of patients requiring intubation at a dose of 0.3
mg/kg IV. Etomidate is widely available, has a rapid onset time, and is appropriate for use in
patients with angioedema. If available, ketamine may be a preferable agent. Induction doses
of ketamine, typically 1.5 mg/kg IV, do not preserve airway reflexes. However, lower doses,
typically below 1mg/kg, may preserve a patient’s abilities to maintain his or her own airway
and be appropriate for awake intubation. Midazolam is slower in onset but can serve as an
induction agent when etomidate and ketamine are not available.
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Paralytics: Paralytics should be used with caution in patients with angioedema. Once given,
the patient will be unable to respire on his or her own and the full responsibility of
maintaining oxygenation and ventilation falls on the provider. If the provider is unable to
intubate and the angioedema prevents effective bag-valve mask ventilation, a
cricothyrotomy may be required. Succinylcholine is the most commonly used paralytic
agent for intubation in the ED, having rapid onset at a dose of 1.5mg/kg IV. Succinylcholine
is contraindicated in the presence of burns, denervating diseases, crush injuries, myopathies,
and other risk factors for succinylcholine-induced hyperkalemia. If these comorbidities are
present, non-depolarizing neuromuscular blocking agents such as rocuronium (1.0 mg/kg)
and vecuronium (0.01 mg/kg) are appropriate alternatives.
Intubation methods: The decision of how best to intubate a patient with angioedema
should be made based upon the patient’s prior history of disease severity and any direct
airway visualization.(47) If the patient has difficult airway predictors, a history of having a
difficult airway, or angioedema so severe that the airway cannot be directly visualized, rapid
sequence intubation with paralysis should not be attempted. Awake intubation using either
video laryngoscopy or fiberoptic nasotracheal intubation should be performed. This allows
for airway management without the removal of a patient’s airway reflexes until the
endotracheal tube has passed through the vocal cords.
For awake intubation, local anesthesia should first be used, including atomized or topical
nasal vasoconstrictors and anesthetic agents, followed by a drying agent such as
glycopyrrolate (0.4–0.8 mg IV) to decrease saliva secretion and facilitate visualization. After
sedation, the intubation can be performed. Nasotracheal intubation should never be
performed blindly in the patient with angioedema as airway distortion makes passage of the
endotracheal tube extremely unlikely and localized trauma may induce further swelling.
However, a fiberoptic nasopharyngeal scope or bronchoscope, if available, may be used to
directly visualize passage of the tube. The endotracheal tube should be pre-loaded onto the
scope and then the scope passed through the nose. Similarly, video laryngoscopy can be
used in patients who are only partially sedated. Additional sedation and a paralytic agent can
be administered as soon as the airway is secured.
In patients without a difficult airway, video laryngoscopy still allows for better intubating
conditions than direct laryngoscopy, resulting in faster times to intubation and an improved
first-pass success rate. A direct laryngoscope may be used with awake laryngoscopy, if
needed, or may be used to intubate the patient directly via rapid sequence with both a full-
dose induction agent and a paralytic if a difficult airway is not predicted.
Patients with angioedema may have such severe edema that passage of an endotracheal tube
through the glottis is impossible, even with advanced fiberoptic or video techniques. In these
cases, a cricothyrotomy will be required. In those patients in whom this is anticipated to be a
possibility, the location of the cricothyroid membrane should be marked prior to any airway
intervention being attempted and, ideally, local anesthetic pre-injected with the
cricothyrotomy kit opened as a “double setup” in case it is needed emergently.
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VII. ACUTE PHARMACOLOGIC TREATMENT OF ANGIOEDEMA
Summary Statement 16. Treatment of angioedema depends on historical
features of the patient and, if available, their preexisting diagnosis.(C) If
angioedema presents with signs of anaphylaxis, epinephrine is
recommended. Standard treatment for histamine-mediated angioedema
includes H1 and H2 antagonists and corticosteroids and may require
epinephrine in life-threatening situations.(A) While generally not effective for
bradykinin-mediated angioedema, these treatments are not contraindicated
and if the putative cause of angioedema is unknown, epinephrine followed by
H1 antagonists and corticosteroids should be given.(C)—If the cause of
angioedema is not apparent, initial standard of care treatment of angioedema should include
epinephrine, H1and H2 antagonists and oral corticosteroids. If the patient manifests other
organ system involvement (wheezing, shortness of breath, chest tightness), urticaria, or drop
in blood pressure consistent with anaphylaxis, epinephrine should be administered.
Epinephrine and oxygen are the most important therapeutic agents administered in
anaphylaxis. Although there are no direct data to demonstrate that antihistamines mitigate
any noncutaneous symptoms, theoretical benefit is possible. (48) Appropriate volume
replacement either with colloid or crystalloids is essential for patients who are clinically
unstable or refractory to initial therapy.
Epinephrine is the drug of first choice for life-threatening histamine-mediated angioedema,
in particular when there is airway swelling or hypotension.(48) It is not contraindicated in
bradykinin-mediated angioedema but may have minimal benefit for severe upper airway
swelling until other drugs and intubation are available. Epinephrine is not indicated for non-
life-threatening angioedema not involving the airway. Epinephrine (0.01 mg/kg of a 1:1000
solution to a maximum of 0.5 mg) is best given intramuscularly for rapid absorption;
intravenous administration should be avoided except in an emergency or code-type
resuscitation. Duration of action is short so repeat dosing may be required if symptoms
persist or return. Adverse effects are short- lived and include increased heart rate, tremor and
anxiety. Use should not be withheld if indicated despite heart disease or other cardiovascular
diseases.
H1 antagonists are the treatment of choice to suppress histamine-mediated angioedema,
although they have no benefit in bradykinin-mediated angioedema.(10) Because H1
antagonists are well-tolerated with minimal adverse effects, other than sedation, they should
be administered in the absence of a clear history of HAE or ACE inhibitor-induced
angioedema. In older adults, side effects can include delirium, urinary retention, constipation
and effects on ocular pressure. For time-critical therapy IV diphenhydramine is the preferred
agent. Doses vary by specific agents. The benefit is limited in anaphylaxis and in airway
swelling; H1 antagonists should never be used in place of epinephrine for these two
emergencies. Low dose or non-sedating agents are preferred if time is not critical. H2
blockers, added to H1 antagonists, may be considered to prevent hypotension and urticaria
associated with pruritus secondary to histamine. There is limited data to support the use of
H2-blockers for allergic emergencies associated with angioedema in the acute setting.(48,
49)
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Corticosteroids are effective for histamine-mediated angioedema.(48) They have little to no
benefit in bradykinin-mediated angioedema. Their action depends on suppression and
activation of many proteins and peptides and onset can take hours to days. They should not
be used as a substitute for epinephrine for this reason. Adverse effects limit long-term use,
but for acute therapy the adverse effects are considered acceptable. Dosing is specific to the
agent. For IV therapy, 60 to 120 mg of methylprednisolone is commonly used, but
randomized studies in angioedema are lacking. In those with allergy to other corticosteroids,
dexamethasone is the preferred agent.
Summary Statement 17. The only potential acute treatment readily available
for the treatment of ACE-induced or other bradykinin-mediated angioedema in
the ED is fresh frozen plasma, which has a risk of viral transmission, allergic
reactions and volume overload, and a possibility of worsening symptoms in
HAE.(B)—Fresh frozen plasma (FFP), which contains variable amounts of C1-INH, may be
used for volume replacement in patients failing initial therapy. It tends to be readily
available, inexpensive and is effective in most cases.(37) There is a possibility of a
hypersensitivity reaction to FFP. Worsening of an HAE attack has been described when FFP
is given, but this has not been documented in the literature for ACE-induced disease.(37)
The worsening of an HAE attack is believed to be due to providing additional substrate that
may potentially worsen attack symptoms.(37) This is primarily of concern only when the
angioedema involves the airway.(37) However, other investigators have reported this
phenomenon with FFP to be rare.(50)
Patients with a history of HAE may be taking anti-fibrinolytics and anabolic androgens for
prophylaxis at the time of attack.(21, 37) Neither have an onset of action fast enough to be
effective for treatment of an attack, although many patients will report taking “extra”
androgen doses when an attack begins. (21, 37) Neither anti-fibrinolytics nor androgens will
interfere with effectiveness of therapies for HAE.(21, 37) However, knowledge that anti-
fibrinolytics and androgens may be prescribed to and used by this population helps identify
these patients as possibly having HAE.(21, 37)
Analgesics and anti-emetics should be prescribed as needed to alleviate the pain and nausea
frequently manifested by HAE patients presenting with an acute abdominal attack. In mild
HAE attacks analgesics and anti-emetics may be all that is needed; however, use of targeted
therapies may mitigate the need for narcotics and result in more rapid resolution of the pain.
Summary Statement 18. Several targeted therapies are now FDA approved in
the United States for the treatment of acute HAE attacks.(A) These novel
therapies, including icatibant, ecallantide and C1-inhibitor concentrate, are
effective for the treatment of HAE attacks and may have benefit in ACE-
induced angioedema, but data are limited to support these treatments for
non-HAE patients.(C)—Bradykinin-mediated angioedema resulting from dysregulation
of the kallikrein-bradykinin pathway is distinct from allergic or histamine-mediated
angioedema.(21, 37) Because bradykinin-mediated angioedema is generally unresponsive to
H1 antagonists, corticosteroids, and epinephrine, five medications targeted at the underlying
pathophysiology have been developed: two purified C1-INH protein concentrates derived
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from pooled donor plasma, a recombinant C1-INH protein product, a kallikrein
inhibitor―ecallantide, and a bradykinin 2-receptor antagonist―icatibant. Of these, three are
FDA approved for attacks of HAE: ecallantide, icatibant and one of the purified C1-INH
protein concentrates. Table 3 summarizes these agents, their mechanism of action, dosing
and side effects.
Human plasma-derived C1-INH concentrate (Berinert- CSL Behring, Marburg, GR)
administration provides the native plasma protein with numerous physiologic inhibitory
functions, including regulation of Factor XII and kallikrein activity thereby reducing
bradykinin production in the setting of C1-INH deficiency. C1-INH protein concentrate is
FDA-approved for the treatment of acute abdominal, facial, or laryngeal attacks of HAE in
adult and adolescent patients, at a dose of 20 U/kg, given intravenously.(51) This dose is
apparently appropriate in children even though it is off label in those patients below 12 years
of age.(52, 53) Another plasma derived C1-inhibitor, Cinryze (Viropharma, Exton, PA,
USA) can also be used off label for HAE attacks in the USA and is approved for the
treatment of HAE in adults in the EU at 1000 units IV. Recombinant human C1-INH
(Ruconest) replaces C1-INH protein activity. It is currently investigational in the United
States, but is licensed in Europe for the treatment of HAE attacks in adults (See Table 3).
(54)
Ecallantide (Kalbitor) is a highly specific plasma kallikrein inhibitor targeted at reducing
kallikrein-mediated production of bradykinin. This product is FDA-approved for the
treatment of acute HAE attacks in patients 16 years and older and is administered by 3
subcutaneous injections (each injection 1cc or 10 mg) for a total dose of 30mg.(55) Due to a
risk of anaphylaxis, which was observed in approximately 3% of study participants,
ecallantide should be administered under the direct supervision of a health care professional
capable of treating hypersensitivity reactions.(37) Since the majority of the anaphylaxis
reactions occurred within 1 hour of use, observation of the patient for at least 60 minutes or
greater following use of ecallantide is recommended.
Icatibant (Firazyr) is a synthetic decapeptide and selective bradykinin-2 receptor antagonist
that blocks the vascular effects of bradykinin. FDA-approved for physician- or patient-
administered treatment of HAE attacks in adults 18 years and older, it is administered by
single subcutaneous injection at a dose of 30 mg.(56) Pain and erythema at the injection site
occurs in the majority (97%) of patients, but this side effect is considered relatively benign
and temporary. As with ecallantide and C1-INH, a second, and rarely a third dose of
icatibant may be necessary.
No randomized comparative studies of the targeted therapies have been conducted and both
trial design and efficacy end points have differed among the studies. Differences also exist
among agents with regard to safety concerns and route of administration. Clinical studies of
HAE-specific agents have also demonstrated that a small subset of HAE attacks (~10%)
require a second dose of medication due to a partial response or recurrence of symptoms.
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Studies examining the efficacy of these agents in ACE-I and acquired angioedema are
ongoing.(57–60) Their use in idiopathic angioedema refractory to histamine-targeted
treatment has not been studied.
VIII. DISPOSITION
Summary Statement 19. There is a paucity of data to guide disposition
decisions for hospitalization versus discharge home for angioedema patients.
The Ishoo criteria provide one potential way for a physician to assess risk and
admission decisions; however, these criteria have not yet been validated.(C)
Risk Stratification: Patient disposition for hospital admission or discharge home should be
determined according to the severity of their airway involvement. The Ishoo classification
includes principles that can be applied to various bradykinin-mediated angioedema
disorders.(33) While this tool does assist the treating physician with information to aid in
risk stratification, it was derived retrospectively, has yet to be validated, and requires the use
of laryngoscopy to stage a patient (Table 4).
Patients in classification stages I and II with only face, lip or soft palate edema can often be
managed as outpatients or admitted to an extended monitoring location (inpatient ward or
observation unit). This is because patients at Ishoo stage I or II and patients with a normal
appearing larynx on nasopharyngoscopy rarely progress to the need for airway intervention.
(61) When the angioedema involves more than three physical sites from among lips, anterior
tongue, floor of mouth, soft palate, base-of-tongue and larynx, there is increased risk of
airway involvement and therefore outpatient management is not recommended.(43)
Generally, all patients with respiratory distress or in need of an airway intervention should
be admitted to an intensive care unit; Patients in Stages III and IV should be cared for in the
intensive care unit.
Role of Observation Units: Patients with mild to moderate angioedema that are admitted to
the inpatient ward can frequently be discharged home within 24 hours.(33) This opens the
possibility of using ED-based observation units. Although not rigorously studied for use in
angioedema, some centers have implemented angioedema protocols in ED-based
observation units, and standardized diagnostic and therapeutic protocols with inclusion/
exclusion criteria and disposition decision aids already exist (http://
www.emergencykt.com/).
Consultation in the Emergency Department: Consultation with anotolaryngologist should
be considered regarding decisions on airway management if time permits. Consultation with
an allergist/immunologist for the treatment of ED patients with acute and/or recurrent
angioedema is unlikely to change the emergent or acute therapeutic course and airway
management. However, consultation may guide the emergency physician in obtaining useful
laboratory testing during the time of an attack, and for ensuring that appropriate follow-up is
arranged. Patients with HAE presenting with angioedema may have targeted therapy
available, and consultation with their HAE specialist, which is most often an allergist/
immunologist, could guide the use of targeted therapies.
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Follow-up: A well-formulated plan with which the treating clinician is comfortable and
follow- up to an appropriate care provider can allow patients with mild to moderate
angioedema to be discharged home and avoid an unnecessary hospital admission. Results
from testing performed in the ED, in particular C4 and tryptase levels, usually require
greater than 24 hours for processing, and therefore should be evaluated during the follow-up
visit. Patients with HAE should have follow-up with a specialist familiar with their disease,
who can be involved in their care.(52) In addition, when it is a patient’s first episode of
angioedema, the attack is unresponsive to H1 antagonists and corticosteroids, and the patient
carries a family history of angioedema, it is important to arrange follow-up with an HAE
specialist which is usually an Allergist/Immunologist, as the patient may have HAE. This
will ensure the patient is educated on HAE triggers, including medications such as estrogens
and ACE-inhibitors, and on procedures including both surgery and invasive dental work.(30)
Moreover, when the patient is in the care of an HAE specialist it is more likely he or she will
have an individualized emergency action plan in place to treat angioedema, which involves
targeted treatments, including home treatment options that may reduce the need for potential
future ED visits.(53, 54) Patients with HAE may present to an ED with their emergency plan
and their medications. As many EDs /hospitals have specific policies regarding the
administration of these “brown bagged” therapies, it is beneficial to have this policy
addressed in advance. When developing an emergency plan, an ED near the patient’s home
should be identified. However, such an arrangement may not always be feasible when
patients travel or are not near their home.
Discharge instructions: When discharged from the ED, patients should have ready access
to at least one specific modality to treat recurrent symptoms. In the case of HAE, this may
include a targeted on-demand therapy.(52) For all other patients, and for suspected HAE
where no targeted therapy is available for self-administration, they should be discharged
with an epinephrine auto-injector kit until seen by an angioedema specialist who can
confirm their diagnosis and the need for specific therapy. Many HAE patients prescribed
pdC1-INH or ecallantide are required to have epinephrine on hand in the event of an allergic
reaction to these agents. The patient and family members or friends should receive training
for self-administration of targeted therapies in case the patient can’t self-administer during
an attack. For patients with known HAE who have on-demand targeted therapy available to
them already, refresher training on self-administration of their rescue medication may be
needed. The patient should be told to return to the ED, their specialist, or their primary care
provider if symptoms persist or worsen.(52) Patients with ACE-inhibitor-induced
angioedema should be told to discontinue their ACE-inhibitor. An alternative anti-
hypertensive agent should be discussed with the patient’s primary care physician, if
possible. Otherwise, the emergency physician should consider starting a substitute agent
until primary care follow-up can be established. Although, a modest risk of recurrent
angioedema may exist in patients with ACE-I angioedema switched to a calcium channel
blocker or an angiotensin receptor blocker (ARB), most patients can safely use these agents
without recurrent angioedema.(62, 63)
Follow-up: A well-formulated plan with follow-up to an appropriate provider can avoid an
admission for the patient with mild to moderate angioedema whom the treating clinician is
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comfortable discharging home. Testing performed in the ED, particularly C4 levels, can be
evaluated during the follow-up visit. HAE patients should have a specialist familiar with the
disease involved in their care.(64) When it is a patient’s first episode of angioedema, the
attack is unresponsive to H1 antagonists and corticosteroids, and the patient carries a family
history of attacks, it is important to arrange follow-up with an allergist/immunologist or
HAE specialist. This will ensure the patient is educated on HAE triggers, including
medications such as estrogens and ACE-inhibitors, and both surgery and dental work.(38)
Moreover, when the patient is in the care of an HAE specialist it is more likely he or she will
have targeted treatment available, including home treatment options that should reduce the
need for ED visits.(65, 66) Patients with HAE will often present to ED with an emergency
action plan and specific therapy prescribed by their treating physician for home use or to
take to an ED for administration in the event of emergency. It is encouraged that ED/
hospitals change policies if necessary to allow the administration of these ‘“brown bagged”
therapies as directed in emergent situations.
Discharge instructions: When discharged from the ED, patients should have ready access
to at least one specific modality to treat recurrent symptoms. In the case of HAE, this should
include a targeted on-demand therapy.(64) For all others, and for suspected HAE where no
targeted therapy is available for self-administration, they should be discharged with
epinephrine until seen by an angioedema specialist who can confirm their diagnosis and
appropriate therapeutic intervention. HAE patients on C1-INH or ecallantide are required to
have epinephrine on hand in the event of an allergic reaction to these agents. The patient and
any available friends or family should receive training for self-administration of targeted
therapies. For patients with known HAE who have on-demand targeted therapy available to
them already, refresher training on self-administration of their rescue medication may be
needed. Most HAE specialists advocate for self-therapy to help ensure early treatment
leading to shorter duration and less severe attacks, which may result in a reduction in
absenteeism and morbidity and even potential mortality. The patient should be told to return
to the ED, their specialist or their primary care provider if symptoms persist or worsen
despite therapy.(64) Emphasis should be placed on the necessity for patients with upper
airway swelling to self-treat without delay and present to the ED for observation since not
all cases respond to therapy. Patients with ACE-inhibitor-induced angioedema should be
told to discontinue their ACE-inhibitor. An alternative agent should be discussed with the
patient’s primary care physician, if possible. Otherwise, follow-up with a primary care
physician to start a new anti-hypertensive or starting a substitute agent at the discretion of
the emergency physician should be performed.
REMAINING CONTROVERSIES
As the parameter was developed, several areas were identified that required further
investigation, including:
1. The use of novel pharmaceutical agents (C1-INH, kallikrein inhibitor or bradykinin
receptor antagonist) in patients with ACE-inhibitor-induced or HAE with normal
C1-INH.
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2. The use of novel pharmaceutical agents (C1-INH, kallikrein inhibitor or bradykinin
receptor antagonist) in patients whose poor response to conventional therapy
suggests they have non-HAE non-histamine mediated angioedema which could be
bradykinin mediated.
3. A validated clinical decision algorithm to identify patients who require
nasopharyngoscopy.
4. The use of other modalities to assess the airway in patients with angioedema of the
head and neck due to the potential unavailability of nasopharyngosopy.
5. A point of care or laboratory based test that can be used to rapidly differentiate
bradykinin-mediated angioedema from other forms of angioedema.
6. Comparative-effectiveness studies to guide disposition decision-making and
follow-up.
7. Head to head comparisons of available therapies to determine the most effective
intervention for emergency care of the patient with ACE-induced angioedema or
HAE
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Figure 1. Algorithmic Approach to the Management of Angioedema in the ED
Employing a simple classification scheme for angioedema can help in developing an
efficient and effective approach to assessing and managing patients presenting with
angioedema. The first step in managing any patient in the emergency department is to
sufficiently manage the airway and breathing, as well as to support circulatory function if
necessary. Once the patient is stabilized a focused history and physical should be obtained to
separate bradykinin-mediated (ACE-induced, HAE) from histamine-mediated. Subsequent
distinctions between the underlying causes of angioedema can then be made to ensure
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appropriate longitudinal management and follow-up care. If the patient is on an ACE
inhibitor, stop medication and provide airway management support. If the patient has a
known history of hereditary angioedema, treat according to HAE guidelines using one of the
recommended “on demand” therapies (Table 2).(37) If the patient has signs of anaphylaxis
(i.e., hypotension, vomiting, vasculature instability), administer epinephrine and treat
according to anaphylaxis guidelines.(48)
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Table 4
Ishoo Classification for Monitoring Severity of the Upper Airway
Stage Clinical Findings Disposition
I Facial rash, facial edema, lip edema Home or admission
II Soft palate edema Home or admission
III Lingual edema Intensive care unit
IV Laryngeal edema Intensive care unit
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